PAMVATAMIG
UNII X3U67W8G5W

Substance Identification & Data

This profile provides standardized clinical and technical data for Pamvatamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) X3U67W8G5W.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2750004-05-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

X3U67W8G5W

CAS Registry Number

2750004-05-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PAMVATAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C179831

National Cancer Institute reference terminology for clinical and research data.

INN ID

12549

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-136

Identifier assigned by the United States Adopted Names Council.

Substance Type

Pamvatamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Pamvatamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Pamvatamig

Common Names & Synonyms

Gamma1 heavy chain anti-MET Homo sapiens (1-452)[VH (Homo sapiens IGHV7-4-1*02 (95.9%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123)-Homo sapiens IGHG1*03, G1m3, nG1m1CH1 R120, E12, M14, G1v72 CH3 D7, E24 (CH1 R120(220) (124-221), hinge 1-15 (222-236), CH2 (237-346),CH3 E12 (362), M14 (364), L7>D (357), L24>E (374)(347-451), CHS K2>del (452)) (124-452)], (226-214')-disulfide with common kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01(100%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01(100%), Km3 A45.1 (153), V101 (191) (108'-214')],gamma1 heavy chain anti-EGFR Homo sapiens (1''-451'') [VH (Homo sapiens IGHV1-18*01 (98.0%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.15] (26''-33''.51''-58''.97''-111'')) (1''-122'')-Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, E12, M14,G1v73 CH3 K7, K22 (CH1 R120 (219'') (123''-220''),hinge 1-15 (221''-235''), CH2 (236''-345''), CH3 E12(361''), M14 (363''), L7>K (356''), T22>K (371'') (346''-450''), CHS K2>del (451'')) (124''-452'')], (226''-214''')-disulfide with common kappa light chain Homo sapiens (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-39*01(100%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'''-32'''.50'''-52'''.89'''-97''')) (1'''-107''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'''), V101 (191''')(108'''-214''')], dimer (232-231'':235-234'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)

Immunoglobulin G1 [357-aspartic acid,374-glutamic acid,de-C-terminal-lysine], anti-(human hepatocyte growth factor receptor c-Met) (human monoclonal MCLA-129 γ1-chain), disulfide with human monoclonal MCLA-129 κ-chain, (232→231′),(235→234′)-bis(disulfide) with immunoglobulin G1 [356-lysine,371-lysine,de-C-terminal-lysine] anti-(human epidermal growth factor receptor) (human monoclonal MCLA-129 γ1-chain) disulfide with human monoclonal MCLA-129 κ-chain

Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific

MCLA 129 [WHO-DD]

PAMVATAMIG [USAN]

pamvatamig [INN]